Medpace Holdings Inc (NASDAQ:MEDP) was the recipient of a significant decrease in short interest in August. As of August 15th, there was short interest totalling 407,140 shares, a decrease of 32.6% from the July 31st total of 604,099 shares. Currently, 2.0% of the shares of the company are sold short. Based on an average daily trading volume, of 1,022,072 shares, the short-interest ratio is presently 0.4 days.

In related news, CEO August J. Troendle sold 731,460 shares of the stock in a transaction on Monday, August 6th. The shares were sold at an average price of $59.26, for a total transaction of $43,346,319.60. Following the sale, the chief executive officer now directly owns 849,621 shares of the company’s stock, valued at $50,348,540.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Medpace Limited Partnership sold 5,224,997 shares of the stock in a transaction on Monday, August 27th. The stock was sold at an average price of $54.75, for a total transaction of $286,068,585.75. The disclosure for this sale can be found here. Insiders have sold 14,510,659 shares of company stock worth $758,531,950 over the last three months. 29.50% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp raised its position in shares of Medpace by 4.3% in the second quarter. Bank of New York Mellon Corp now owns 85,341 shares of the company’s stock valued at $3,670,000 after buying an additional 3,486 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of Medpace in the second quarter valued at about $3,812,000. MetLife Investment Advisors LLC raised its position in shares of Medpace by 54.8% in the second quarter. MetLife Investment Advisors LLC now owns 5,868 shares of the company’s stock valued at $252,000 after buying an additional 2,077 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its position in shares of Medpace by 57.1% in the second quarter. Metropolitan Life Insurance Co. NY now owns 4,144 shares of the company’s stock valued at $178,000 after buying an additional 1,507 shares during the last quarter. Finally, Macquarie Group Ltd. raised its position in shares of Medpace by 135.3% in the second quarter. Macquarie Group Ltd. now owns 8,000 shares of the company’s stock valued at $344,000 after buying an additional 4,600 shares during the last quarter. 39.31% of the stock is currently owned by institutional investors and hedge funds.

MEDP opened at $56.86 on Wednesday. The company has a current ratio of 0.68, a quick ratio of 0.68 and a debt-to-equity ratio of 0.32. The firm has a market cap of $1.97 billion, a price-to-earnings ratio of 37.41, a P/E/G ratio of 1.42 and a beta of 1.16. Medpace has a 52-week low of $30.62 and a 52-week high of $63.97.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Tuesday, July 31st. The company reported $0.61 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.42 by $0.19. The business had revenue of $117.80 million for the quarter, compared to the consensus estimate of $104.97 million. Medpace had a net margin of 10.44% and a return on equity of 14.22%. The company’s revenue was up 24.5% compared to the same quarter last year. During the same period last year, the firm posted $0.38 earnings per share. research analysts anticipate that Medpace will post 2.44 earnings per share for the current fiscal year.

Several equities analysts have issued reports on the stock. Zacks Investment Research downgraded shares of Medpace from a “hold” rating to a “sell” rating in a report on Wednesday, May 2nd. BidaskClub downgraded shares of Medpace from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 31st. ValuEngine raised shares of Medpace from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. Credit Suisse Group increased their price objective on shares of Medpace from $42.00 to $49.00 and gave the company an “outperform” rating in a report on Tuesday, July 31st. Finally, William Blair raised shares of Medpace from a “market perform” rating to an “outperform” rating in a report on Tuesday, July 31st. Six analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $43.83.

Medpace Company Profile

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Featured Article: Price to Earnings Ratio (PE) Basics

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.